课题基金 / 基金详情

Neuroprotective efficacy of a melatonin analog in traumatic brain injury

Neuroprotective efficacy of a melatonin analog in traumatic brain injury
褪黑激素类似物对创伤性脑损伤的神经保护作用
批准号:
7053659
负责人:
SOMASUNDAR PRASAD GABBITA
金额:
$17.74万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-01 至 2008-08-31

项目摘要

项目成果

SOMASUNDAR PRASAD GABBITA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of this Phase 1 SBIR proposal is to determine whether the melatonin analog PD6735 (6-chloro- (R) B-methyl melatonin) is neuroprotective in a rat traumatic brain injury (TBI) model. A critical and largely unmet need exists for effective TBI neuroprotectant drugs. Free radicals and neuroinflammatory components mediate brain cortical tissue damage resulting in significant neurologic deficits after TBI. Preliminary Studies suggest that PD6735, like its structural parent melatonin, is an effective neuroprotectant in a rat TBI model. In these studies brain cortical tissue damage was assessed by quantitative morphometry in PD6735-treated TBI rats. PD6735 reduced cortical tissue damage by 68 % compared to vehicle in TBI animals (P= 0.01). In an in vitro assay of brain injury, PD6735 was three- to six-fold superior in inhibiting free radical and neuroinflammatory mediator production compared to melatonin suggesting a possible mechanism of the PD6735-induced neuroprotection observed in vivo. A total of ten Phase 1 and Phase 2 clinical studies demonstrate that PD6735 is safe and well tolerated in humans in doses up to 100 mq and lacks any adverse side effects compared to placebo. In contrast, melatonin produces significant clinically adverse events in humans at doses greater than 1 mg. PD6735's neuroprotective properties in vivo and in vitro combined with its safety and tolerance in humans at high doses form the underlying rationale for the proposed rat TBI drug efficacy study. We hypothesize that PD6735 will exhibit robust neuroprotective efficacy by reducing cortical tissue damage and neurologic deficits in TBI rats. Given PD6735's safety and tolerability in humans, positive results in the proposed rat TBI study will allow rapid initiation of PD6735 clinical studies in TBI patients. Our Specific Aim is: Specific Aim: Determine PD6735's neuroprotective effect on spatial learning and memory employing the Morris water maze and brain cortical tissue damage employing quantitative morphometry in TBI rats. The three controls included will be sham TBI rats, vehicle-, and melatonin-(as structural control) treated TBI rats.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting Latexin for radiation mitigation.
  • 批准号:
    9925204
  • 项目类别:
  • 资助金额:
    $28.43万
  • 财政年份:
    2019
  • 负责人:
    SOMASUNDAR PRASAD GABBITA
  • 依托单位:
A Novel Small Molecule TNF-alpha Inhibitor as a Disease-Modifying Alzheimer's Disease Drug Treatment
  • 批准号:
    9466541
  • 项目类别:
  • 资助金额:
    $69.69万
  • 财政年份:
    2015
  • 负责人:
    SOMASUNDAR PRASAD GABBITA
  • 依托单位:
A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment.
  • 批准号:
    8980560
  • 项目类别:
  • 资助金额:
    $74.53万
  • 财政年份:
    2015
  • 负责人:
    SOMASUNDAR PRASAD GABBITA
  • 依托单位:
A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment.
  • 批准号:
    9134606
  • 项目类别:
  • 资助金额:
    $74.46万
  • 财政年份:
    2015
  • 负责人:
    SOMASUNDAR PRASAD GABBITA
  • 依托单位:
国内基金
海外基金
基于MFSD2A调控血迷路屏障跨细胞囊泡转运机制的噪声性听力损失防治研究
  • 批准号:
    82371144
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    汪雪玲
  • 依托单位:
内源性蛋白酶抑制剂SerpinA3N对缺血性脑卒中后血脑屏障的保护作用及其表达调控机制
  • 批准号:
    82371317
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    万杰清
  • 依托单位:
KLK10调控胶质—血管耦合与对话促缺血性卒中后血脑屏障修复的机制
  • 批准号:
    82371465
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    李龙宣
  • 依托单位:
Sitagliptin通过microbiota-gut-brain轴在2型糖尿病致阿尔茨海默样变中的脑保护作用机制
  • 批准号:
    81801389
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    21.0万元
  • 批准年份:
    2018
  • 负责人:
    田茗源
  • 依托单位: